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Synopsis
Alterations in genomic CpG methylation patterns have been found to be associated with cell transformation and
neoplasia. Although it is recognized that methylation of CpG residues negatively regulates gene expression, how the
various MBPs (methyl-binding proteins) contribute to this process remains elusive. To determine whether the two
well characterized proteins MeCP2 (methyl-CpG-binding protein 2) and MBD1 (methyl-CpG-binding domain 1) have
distinct or redundant functions, we employed RNAi (RNA interference) to silence their expression in the prostate
cancer-derived PC3 cell line, and subsequently compared cell growth, invasion and migration properties of these cell
lines in addition to their respective mRNA-expression profiles. Cells devoid of MeCP2 proliferated more poorly com-
pared with MBD1-deficient cells and the parental PC3 cells. Enhanced apoptosis was observed in MeCP2-deficient
cells, whereas apoptosis in parental and MBD1-deficient cells appeared to be equivalent. Boyden chamber invasion
and wound-healing migration assays showed that MBD1-silenced cells were both more invasive and migratory com-
pared with MeCP2-silenced cells. Finally, gene chip microarray analyses showed striking differences in the mRNA-
expression profiles obtained from MeCP2- and MBD1-depleted cells relative to each other as well as when compared
with control cells. The results of the present study suggest that MeCP2 and MBD1 silencing appear to affect cellular
processes independently in vivo and that discrete sets of genes involved in cellular proliferation, apoptosis, invasion
and migration are targeted by each protein.
Key words: DNA methylation, gene expression, methyl-binding protein (MBP), methylated CpG (mCpG), RNA
interference (RNAi)
INTRODUCTION
DNA methylation and histone modifications are two well-known
epigenetic mechanisms that have an impact on gene expression
[1]. Locus-specific DNA methylation, as well as demethylation,
is required during normal development to ascertain that expres-
sion of selected genes is restricted to certain tissues. Once esta-
blished, un-programmed changes in genomic DNA-methylation
patterns have the potential to accidentally turn on or off genes
involved in diverse cellular functions, including cell cycle, migra-
tion, apoptosis and invasion, leading sometimes to disease [2–5].
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations used: CDK, cyclin-dependent kinase; FCS, fetal calf serum; GFP, green fluorescent protein; HDAC, histone deacetylase; MBD, methyl-CpG-binding domain;
MBP, methyl-binding protein; MCM, minichromosome maintenance; mCpG, methylated CpG; MeCP2, methyl-CpG-binding protein 2; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide; RAR-β, retinoic acid receptor β; RASSF1A, Ras association domain family protein 1A; RT-PCR, reverse transcription-PCR; shRNA, small-hairpin RNA; TRD,
transcriptional repression domain.
1To whom correspondence should be addressed (email farhat.bbs@gmail.com).
Malignancies are normally characterized by widespread hypo-
methylation of the genome and site-specific hypermethylation of
tumour-suppressor genes [6].
The negative effect of DNA methylation on gene expression
is mediated by the binding of MBPs (methyl-binding proteins)
to mCpGs (methylated CpGs) with subsequent recruitment of
repressor complexes [7]. The five main members of the MBD
(methyl-CpG-binding domain) family of proteins are MBD1,
MBD2, MBD3, MBD4 and MeCP2 (methyl-CpG-binding pro-
tein 2); a sixth member, Kiaso, is structurally unrelated to
the other MBPs but represses transcription in a methylation-
dependent manner [8]. MeCP2, the first member of this
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family to be identified, is encoded by a four exon gene. Detailed
analyses of MeCP2 functional domains have revealed an MBD
and a TRD (transcriptional repression domain) which recruits a
repressor complex, including mSin3A (murine Swi-independent
3A) along with HDAC (histone deactylase) 1 and HDAC2 [9].
MeCP2 binds preferentially to mCpGs adjacent to A/T-rich se-
quences, and MBD2 also appears to have sequence specificity
which allows it to target specific genes [10,11]. MBD3 is a non-
DNA-binding protein, but influences gene expression by forming
a heterodimer with MBD2 [12]. As a thymine DNA glycosylase,
MBD4 is involved in DNA repair, but can also repress transcrip-
tion [13].
MBD1 has a TRD, three centrally located cysteine-rich CXXC
motifs and a highly conserved MBD domain at its N-terminus.
The third CXXC motif is needed for methylation-independent
DNA binding [14]. MBD1 mediates transcription repression
by recruiting HDAC3 [15]. Preserving the repressive state
of chromatin during chromosomal replication is also an activity of
MBD1 which it performs by forming a transient S-phase com-
plex with histone methylase SETDB1 (SET domain, bifurcated 1)
and CAF1 (chromatin assembly factor 1) that uses mCpG during
replication to modify chromatin [16].
Although MeCP2 and MBD1 bind to hypermethylated gene
promoters and subsequently recruit repressor complexes to shut
down gene transcription, whether their gene targets are specific or
overlapping has thus far remained unclear. To address this issue,
we focused our attention on MeCP2 and MBD1, and compared
side-by-side cellular processes, such as proliferation, apoptosis,
invasion and migration, in addition to mRNA-expression profiles
of two cell lines in which the expression of MeCP2 and MBD1
had been silenced. Our results suggest that discrete sets of genes
are supervised by MeCP2 and MBD1 in PC3 cells.
MATERIALS AND METHODS
Cell culture
The PC3 cell line was obtained from the A.T.C.C. and was main-
tained in RPMI 1640 medium at 37◦C with 10% (v/v) FCS (fetal
calf serum), 2 mM L-glutamine, and 100 units/ml penicillin and
streptomycin sulfate (Invitrogen).
Transfections
psiRNATM plasmids are a family of expression vectors designed
to generate shRNAs (small-hairpin RNAs) from an RNA III pro-
moter (Invivogen). PC3 cells were transfected with a mock plas-
mid (control) and with plasmids validated previously which ex-
press shRNAs that target MBD1 and MeCP2 mRNAs, to produce
psiMBD1 (MBD1 silenced) and psiMeCP2 (MeCP2 silenced)
cell lines respectively. These vectors also harbour a GFP (green
fluorescent protein)–zeocin fusion cassette for selection and for
gauging transfection efficiency. Transfections were carried out
using 3 μl of FuGENETM 6 (Roche) and 1 μg of plasmid DNA.
After 48 h of transfection, cells were trypsinized, diluted 1:15
and cultured in medium containing 50 μg/ml zeocin (Invivo-
gen), which was replaced with fresh medium every 3 days. After
3 weeks, resistant colonies (200–300 clones) were trypsinized,
combined into pools, cultured in selection medium and expanded
into cell lines.
PCR
RT-PCR (reverse transcription-PCR) was performed to confirm
silencing of the target genes. Total RNA was extracted from con-
trol PC3 cells as well as from the silenced PC3 cell lines using
TRIzol (Invitrogen). Reverse transcription was carried out with
1 μg of total RNA using the First-Strand Reverse Transcription
kit (Invitrogen) following the manufacturer’s instructions. Sub-
sequently, 2 μl of this reverse transcription reaction was used for
PCR. Oligonucleotide primer sets corresponding to MBD1 and
MeCP2 were purchased from Santa Cruz Biotechnology. Semi-
quantitative RT-PCR for MBD1 was carried out as follows: 1
cycle of 94◦C for 2 min, and 35 cycles of 94◦C for 30 s, 54◦C for
1 min and 72◦C for 1 min, followed by 72◦C for 7 min. Thermo-
cycling conditions for MeCP2 were identical to the conditions
for MBD1, except that the annealing temperature used was 52◦C.
Nested PCR conditions for MBD1 and MeCP2 were: 1 cycle of
94◦C for 2 min, and 20 cycles of 94◦C for 30 s, 56◦C for 1 min
and 72◦C for 1 min, followed by 72◦C for 7 min. Real-time PCR
was carried out on a Chrome 4 real-time cycler (Bio-Rad) for
detecting and quantifying the expression of MBD1 and MeCP2
mRNAs in stably transfected cells using SYBR Green master mix
and optimized primers (Superarray Biotechnology) following the
manufacturer’s instructions.
Western Blotting
Extracts from control, MeCP2- and MBD1-silenced cell lines
were prepared by resuspending cell pellets (approx. 2×105
cells) directly in sample loading buffer [0.125 M Tris/HCl
(pH 6.8), 4% (w/v) SDS, 20% (v/v) glycerol and 10% (v/v) 2-
mercaptoethanol]. Approx. 50 μg of the protein was resolved
by SDS/PAGE (10% gels) and proteins were transferred on
to nitrocellulose membranes (Amersham Biosciences). After
blocking overnight at 4◦C in 5% (w/v) non-fat dried skimmed
milk powder prepared in TBST (Tris-buffered saline with 0.1%
Tween 20), membranes were probed with antibodies against
MeCP2, MBD1 and MCM2 (minichromosome maintenance 2)
(all used at 1:1000 dilution; Santa Cruz Biotechnology) for 1–
2 h at room temperature (25◦C). After washing, membranes were
incubated for 30 min at room temperature with the appropri-
ate HRP (horseradish peroxidase)-conjugated secondary anti-
bodies and subsequently developed with the ECL® (enhanced
chemiluminescence) Western blotting system (Amersham). Actin
was included as the internal loading control and detected using
a specific anti-β-actin antibody (1:1000 dilution; Santa Cruz
Biotechnology).
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide] assay
Cellular proliferation was measured using the MTT proliferation
assay kit (A.T.C.C.) according to the manufacturer’s instructions.
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Briefly, 104 cells were seeded in 96-well plates and cultured in
5% (v/v) FCS for 24 h. Before testing, 10 μl of the MTT labelling
reagent (5 mg/ml MTT) was added to cells and the mixture was
incubated for a further 4 h at 37◦C. Solubilizing reagent (100 μl)
was added and the plate was incubated overnight at 37◦C to
dissolve the formazan crystals. Absorbance was measured at an
absorbance (A) of 595 nm on a Chameleon multilabel detection
platform (Hidex). Each assay was carried out in triplicate and
each experiment was repeated at least twice.
Apotosis assays
Apoptosis was measured by Acridine Orange and ethidium brom-
ide staining as described previously [17] with some modifica-
tions. Briefly, 25 μl of a cell suspension (1×105–2×105 cells)
was added to 25 μl of Acridine Orange/ethidium bromide solu-
tion [1:1 (v/v)] (both Acridine Orange and ethidium bromide
were prepared at 100 μg/ml in PBS) and loaded on a haemocyt-
ometer under a coverslip. Cells were counted on a grid under
visible light and then dead cells (stained orange with ethidium
bromide) were counted under fluorescent light. A Student’s t test
was performed to assess the statistical significance of the res-
ults obtained. Transfected cells (105 cells) were also grown on to
coverslips and stained with Acridine Orange and ethidium brom-
ide after fixation with 100% methanol. These cells were visual-
ized using an epifluorescence microscope and photographed at
×100 magnification.
Boyden chamber invasion assay
The Boyden chamber invasion assay was performed as described
previously [18] with some modifications. A fixed number of cells
(5×104 cells/ml) in serum-free medium were placed into the up-
per chamber of the Boyden chamber, which had been pre-coated
with Matrigel (polyvinyl pyrrolidone-free polycarbonate filter
with 8-μm-pore-size) inserts (BD Pharmingen). The lower cham-
ber contained serum-free medium supplemented with epidermal
growth factor (50 ng/ml; Invitrogen). Cells were incubated for
24 h, after which time the medium was removed and the upper
surface of the invasion chamber insert was scrubbed with a cotton
swab three times in each direction. The membrane was removed
from the invasion chamber insert with a scalpel, fixed with 100%
methanol and stained with Giemsa Wright stain. Cells were coun-
ted at ×400 magnification in five different random fields by two
independent observers. A Student’s t test was performed to assess
the statistical significance of the invasion results obtained.
Gelatin zymography
Gelatin zymography was carried out using conditioned medium
in which cells had been cultured for 24 h. Total protein in the
medium was dialysed and the concentration of protein estimated,
and 20 μg of protein was subjected to SDS/PAGE (8% gels)
co-polymerized with gelatin (2 mg/ml) under non-reducing con-
ditions. Gels were washed three times with 2.5% (v/v) Triton
X-100 for 20 min each and incubated for 18 h at 37◦C in en-
zyme assay buffer [50 mM Tris/HCl (pH 7.5) and 5 mM CaCl2]
to develop enzyme activity bands. After incubation, the gels were
stained with 0.05% Coomassie Brilliant Blue G-250 in a mixture
of methanol/acetic acid/water [2.5:1:6.5 (by vol.)] and de-stained
in 4% (v/v) methanol with 8% (v/v) acetic acid. Gelatinolytic acti-
vities were detected as transparent bands against the background
of Coomassie Brilliant Blue-stained gelatin.
Cell migration assay
Stably transfected cells were sub-cultured in 6-well plates and
incubated in RPMI 1640 medium with 10% (v/v) FCS. Confluent
monolayer cells were serum-starved and incubated in the absence
of growth factors in RPMI 1640 medium for 24 h, and a wound
(1 mm thick) was created using a 10 μl micropipette tip. Cells
were washed and incubated in serum-free medium. Cell migration
was monitored at 12 h intervals and photographed.
Gene chip expression arrays
Total RNA was extracted from psiMBD1, psiMeCP2 and con-
trol cells by ArraygradeTM Total RNA isolation kit (SuperArray
Biosciences), following the manufacturer’s instructions. The in-
tegrity of the RNA was assessed by resolving 1 μg of RNA on
a denaturating agarose gel. The Truelabelling-AMP-2.0 kit (Su-
perarray Biosciences) was used to convert total RNA into biot-
inylated cRNA. The biotinylated probe was then hybridized to a
prostate-cancer-specific oligoGEarray (Superarray Biosciences)
and, after washing, was developed using a Chemiluminescence
detection kit (Amersham Biosciences) and the image was cap-
tured on an X-ray film. The X-ray film pattern was scanned
and loaded on the GEarray Expression Analysis Suite web-based
software (Superarray Biosciences) for analysis. The relative ex-
pression of 288 genes was assessed using this software and nor-
malized against the spot intensities of house-keeping genes [e.g.
actin, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and
ribosomal proteins] detected on the membrane.
RESULTS
Validation of MBD1-silenced as well as
MeCP2-silenced prostate-derived PC3 cell lines
To address whether the genes targeted by MBD1 and MeCP2
are distinct or overlapping, we engineered two cell lines in
which their respective expression was silenced by RNAi (RNA
interference). For this, prostate cancer-derived PC3 cells were
stably transfected with the plasmid vectors psiRNA-MeCP2 and
psiRNA-MBD1, each expressing shRNAs designed to specific-
ally abrogate the expression of their target genes. Both plasmids
expressed GFP, which allowed for easy monitoring of their cellu-
lar expression by epifluorescence microscopy. After maintaining
the transfected cell lines by treatment with zeocin-containing me-
dium for 2 weeks, mRNA levels from psiMeCP2 and psiMBD1
cells were determined by semi-quantitative RT-PCR as well as
real-time PCR. Semi-quantitative RT-PCR analysis was carried
out using a thermocycling program of 55 cycles, with the first
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Figure 1 Silencing of MBD1 and MeCP2 expression in PC3 cells
and validation of cell lines
Total RNA and protein was extracted from mock transfected (Con-
trol), psiMBD1 and psiMeCP2 PC3 cells. (A) RNA was subjected to
semi-quantitative RT-PCR analysis. (B and C) Proteins were Western
blotted with MBD1- and MeCP2-specific antibodies. β-Actin was used
as a loading control.
35 cycles of PCR carried out using the outer primers, followed
by 20 cycles of PCR with the nested primers. Agarose-gel elec-
trophoresis analysis of the nested PCR products revealed that
although the mRNAs for both MBD1 and MeCP2 were present
in the psiMBD1 and psiMeCP2 cell lines respectively, their
levels were significantly lower when compared with the mock-
transfected PC3 cells (Figure 1A). Real-time PCR analysis also
showed that after 40 cycles, MBD1 mRNA could not be detected
in significant amounts in the psiMBD1 cells and that MeCP2
mRNA levels were reduced by 50% in psiMeCP2 cells (results
not shown). Western blotting was also employed to determine the
amounts of remaining MBD1 and MeCP2 in the silenced cell lines
as well as in control cell lines. This revealed that trace amounts of
MBD1 were still present in the psiMBD1 cells (Figure 1B), and
the amount of MeCP2 protein was reduced by approx. 50% in
psiMeCP2 cells relative to the control cells (Figure 1C). Overall,
validation of both cell lines showed that MBD1-specific siRNA
reduced expression of its target by greater than 80%, whereas the
attempted silencing of MeCP2 in PC3 cells resulted in only 50%
reduction in its expression levels, despite the fact that 100% of the
cells were GFP positive. Additional attempts at further reducing
the expression of MeCP2 in the PC3 cell line were unsuccessful.
MBD1 and MeCP2 silencing produces different
phenotypes in PC3 cells
The effect of selectively silencing the expression of MeCP2 and
MBD1 in PC3 cells on their growth and survival was studied
by employing the MTT assay. It revealed a dramatic retarda-
tion of growth in both of the silenced cell lines when compared
with control cells at 24 and 48 h (P< 0.0001 and P< 0.0001
respectively) (Figure 2A). Cells devoid of MeCP2 grew more
poorly than those in which MBD1 expression had been silenced.
The observed growth defect was found to be a consequence of
an enhanced rate of apoptosis, which in the psiMeCP2 cell line
was approx. 2.5-fold greater than both control and psiMBD1 cell
lines (P< 0.0164) (Figures 2B and 2D). The amount of the well
known proliferation marker MCM2 in the three cell lines was
quantified with Western blotting. This experiment showed that
gradually lower amounts of MCM2 were found in the psiMBD1
and psiMeCP2 cells compared with control cells (Figure 2C),
indicating a robust correlation between MCM2 levels and the
proliferation rate of the respective cell lines.
The psiMBD1 cells were significantly more invasive than their
psiMeCP2 counterparts, as demonstrated by the Boyden cham-
ber invasion assay (P< 0.0008) (Figure 3A). Since invasive cells
are known to secrete different matrix metalloproteinases that de-
grade the basement membrane, allowing cells to escape, gelatin
zymography was performed on conditioned medium obtained
from the control and silenced cells. This experiment showed that
psiMBD1cells produced higher amounts of the 72 kDa protein
MMP2 (matrix metalloproteinase 2) compared with both the less
invasive psiMeCP2 and control cells (Figure 3B).
The migratory potential of the psiMeCP2 and psiMBD1 cells
was also evaluated by using the wound-healing assay. Here, con-
trol cells were able to cross the trough after 48 h. In comparison,
psiMBD1 cells migrated slower than the control cells, but signi-
ficantly faster than psiMeCP2 cells (Figure 4).
Expression of discrete sets of genes is influenced
by MBD1 and MeCP2 silencing
Finally, mRNA expression profiles were obtained from MBD1-
depleted cells, MeCP2-depleted cells and control cells by using
a gene chip microarray spotted with a total of 288 oligonuc-
leotides (including 25 control oligonucleotides) representing dif-
ferent genes implicated in prostate cancer. For this, total RNA
was isolated from the three cell lines, labelled and hybridized to
the arrays. The mRNA profiles obtained from all three cell lines
are shown in Table 1. Quantitative analysis and normalization of
the developed spots against housekeeping genes using the GE-
array Expression Analysis Suite software showed that although
the expression of a vast majority of genes in both control and
psiMBD1 cells remained unchanged, expression of nine (out of
263) genes was found to be increased by at least 2-fold when
MBD1 levels were reduced. Similarly, although levels of most of
the expressed genes in both control and MeCP2-deficient cells
also remained constant, nine completely different sets of genes
were found to be up-regulated in the absence of MeCP2.
DISCUSSION
In the present study, we demonstrate that silencing of the two
methyl-CpG DNA-binding proteins MBD1 and MeCP2 produces
cellular phenotypes that are markedly different from each other
in terms of their ability to proliferate, invade and migrate. By
employing the prostate-cancer-derived PC3 cell line, and redu-
cing markedly the expression of MBD1 or MeCP2 by RNAi, we
found significant phenotypic differences between the psiMBD1
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Figure 2 Effect of MBD1 and MeCP2 silencing on cell proliferation
(A) Cells [control, MBD1-depleted (psiMBD1) and MeCP2-depleted (psiMeCP2) cell lines] were grown and their respective
rate of proliferation was measured using the MTT assay after culture for 24 and 48 h. Results are means +− S.E.M. (n= 2)
with each experiment performed in triplicate. (B) Apoptosis was measured by ethidium bromide and Acridine Orange
staining of control, MBD1-depleted and MeCP2-depleted cells. Results are means +− S.E.M. (n= 3). (C) Western blotting
of MCM2 expression in the silenced (psiMBD1 and psiMeCP2) and control cell lines. Band intensities of MCM2 (α-MCM2)
and β-actin were used to normalize MCM2 expression in the three cell lines (shown below the blot). (D) Acridine Orange
and ethidium bromide staining of control, psiMBD1 and psiMeCP2 cells grown on coverslips and fixed with 100% methanol,
with the epifluorescene images captured at ×100 magnification.
and psiMeCP2 cells. For example, proliferation of both cell lines
decreased sharply, but was much more dramatic for psiMeCP2
cells. Additionally, both wound-healing and Boyden chamber
assays revealed that psiMBD1cells had a greater invasion and
migratory potential compared with their psiMeCP2 counterparts.
Even a 50% reduction in MeCP2 expression levels reduced cell
growth markedly. This finding is consistent with the observation
that MeCP2 expression is required for growth of prostate cancer
cells [19]. Poor growth of PC3 cells was found to be the result
of enhanced apoptosis, but could also be attributed to cell-cycle
arrest. Given that MeCP2 has been found to positively influence
c-myc expression [19], it is plausible that depletion of MeCP2
in PC3 cells not only reduced expression of genes such as Cul1,
CDK4 (where CDK is cyclin-dependent kinase) and ornithine
decarboxylase, but also the kinase activity of the CDK2/cyclin
E complex that is required for cell-cycle progression [20–23].
Overall, greater than 80% reduction in MBD1 expression did
not appear to have as significant an effect on the growth of
PC3 cells compared with reducing the expression of MeCP2 by
one-half.
On the basis of the behaviour of the engineered cell lines
in our assays alone, it is tempting to speculate that processes,
such as invasion and migration, are influenced more by MBD1
than MeCP2, which affects cellular growth and apoptosis,
suggesting that both factors affect expression of different sets
of genes. Support for this conclusion stems from the gene
chip microarray results presented, which, although limited,
demonstrate that MBD1 and MeCP2 appear to have distinct
functions in terms of the genes that are targeted by them. Gene
chip experiments showed clearly that although expression of
most genes in the control and silenced cell lines remained
unaltered, expression of two distinct sets of genes was affected
dramatically in the absence of either factor. Among the affected
genes, RASSF1A (Ras association domain family protein 1A)
and RAR-β (retinoic acid receptor β) were most notable, as
both were significantly up-regulated in psiMeCP2 and psiMBD1
cell lines respectively. RASSF1A is a known tumour-suppressor
gene which is heavily methylated in prostate cancers and is
also methylated in PC3 cells [24]. Since RASSF1A is known
to destabilize c-Myc via Ras inactivation [25,26], expression
of RASSF1A is likely to be one reason why MeCP2-deficient
cells grew so poorly. RAR-β is a nuclear-hormone receptor
whose activation by retinoic acid promotes growth arrest and
apoptosis in cancer cells [27], and, given its role, it is plausible
that the retarded growth and enhanced apoptosis observed in
MBD1-silenced cells is a consequence of RAR-β expression.
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Table 1 The impact of MBD1 and MeCP2 silencing on gene expression
List of genes whose expression increased in MBD1-silenced (psiMBD1) and MeCP2-silenced (psiMeCP2) cells by at
least 2-fold relative to the control PC3 cells. The expression profile of each cell line was normalized against housekeep-
ing genes, including actin, GAPDH (glyceraldehyde-3-phosphate dehydrogenase), ribosomal proteins and blank spots
on oligonucleotide arrays. AKAP1, A-kinase-anchoring protein 1; AKT, protein kinase B; BAK1, Bcl2-antagonist/killer 1;
BMP6, bone morphogenetic protein 6; Cant1, calcium-activated nucleotidase 1; Cav1, caveolin 1; CCND1, cell cycle
regulatory protein cyclin D1; MAPK10, mitogen-activated protein kinase 10; NTN4, netrin 4.
Gene Function Fold change
Control cells compared with psiMBD1 cells
AKAP1 Prostate cancer marker 2.9
AKT Anti-apoptotis 2.3
BAX Apoptosis 3.0
BMP6 Growth factor 2.0
CDK6 Cell-cycle regulator 2.6
CDK9 Cell-cycle regulator 2.5
MAPK10 Jun kinase 29.7
Jun Transcription factor 11.7
RAR-β Transcription factor 6.8
Control cells compared with psiMeCP2 cells
BAK1 Apoptosis 3.9
Cant1 Prostate cancer marker 4.0
Cav1 Prostate cancer marker 8.5
CCND1 Cell-cycle regulator 4.1
CD164 Negative regulator of cell proliferation 2.5
Enolase 2 Prostate cancer marker 2.5
RASSF1A Cell-cycle arrest 2.6
NTN4 Extracellular matrix protein 9.7
Figure 3 Cellular invasion assays and zymography analysis
(A) Boyden chamber invasion assays were carried out on control,
MBD1-silenced (psiMBD1) and MeCP2-silenced (psiMeCP2) cell lines
and the number of cells invading the Matrigel was determined. Results
are means +− S.E.M. (n= 2) with each experiment performed in triplic-
ate. (B) Gelatin zymography was carried out with equivalent amounts of
conditioned medium obtained from control and silenced (psiMeCP2 and
psiMBD1) cell lines. MMP2 (matrix metalloproteinase 2) was identified
as a 72 kDa protein.
Figure 4 Cellular migration assays
Wound-healing migration assays were carried out as described in the
Materials and methods section. Images show wounds in control, and
MBD1-silenced (psiMBD1) and MeCP2-silenced (psiMeCP2) cells at 0 h
(A–C) and after 48 h (D–F).
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MBD1 and MeCP2 silencing produces different cell phenotypes
The notion that MeCP2 is a global regulator of methylation-
dependent gene expression was initially based on the observa-
tion that it requires only a single mCpG for binding, but two
key discoveries were instrumental in disputing this claim. First,
a microarray-based study demonstrated MeCP2 targets only a
small set of genes and affects their expression subtly [28].
Secondly, MeCP2 selectively binds to those mCpGs that are
flanked by A/T residues [10,11]. Unlike MeCP2, MBD1 can
bind to mCpG dinucleotides on double-stranded DNA regardless
of its nearest neighbours and seems to be the only MBP without
any sequence preference [29]. Given the mCpG-binding prop-
erties of MBD1 and MeCP2, it is likely that genes targeted by
MeCP2 necessarily serve as platforms for MBD1 binding, but
not vice versa. Thus in situations where expression of MeCP2 is
limiting, MBD1 could potentially compensate for its deficiency.
In the present study, however, we found that MBD1 was unable
to compensate for MeCP2, suggesting that MeCP2 regulates a
set of pro-apoptotic genes either directly or indirectly which are
not targets of MBD1. Interestingly, in addition to mediating its
effect via mCpG residues, MeCP2 has also been shown to repress
its target gene expression in a methyl-CpG independent manner
[19,30].
Taken together, the present study demonstrates that discrete
sets of genes involved in cell proliferation, invasion and migra-
tion are selectively influenced by MBD1 and MeCP2. A de-
tailed microarray-based transcriptome analysis of MBD1- and
MeCP2-silenced cells should be useful for identifying complete
sets of genes that are exclusively or commonly targeted by these
proteins.
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